CLINICAL PHENOTYPES AND MORTALITY RATES OF ALCOHOLIC LIVER CIRRHOSIS IN PATIENTS WITH PREVIOUS COVID-19 INFECTION

X.S.Shodmonova

Authors

X.S.Shodmonova Buxoro davlat tibbiyot institute, Tibbiyot fakulteti talabasi Author

Keywords:

alcoholic liver cirrhosis, COVID-19, clinical phenotype, mortality, decompensation

Abstract

Clinical phenotypes and mortality rates of alcoholic liver cirrhosis in patients with previous COVID-19 infection. This study investigated the clinical phenotypes and mortality outcomes in patients with alcoholic liver cirrhosis (ALC) and a history of COVID-19 infection. A retrospective-prospective observational study was conducted between 2022 and 2024 at the Bukhara Regional Clinical Hospital. A total of 120 patients were analyzed: 68 with prior COVID-19 infection and 52 as controls. The findings revealed that ALC patients with COVID-19 had higher rates of Child-Pugh C (46% vs. 25%, p=0.02), higher MELD scores (19.3 ± 5.2 vs. 15.1 ± 4.7, p=0.01), and increased mortality (35.3% vs. 17.3%, p=0.03). These results suggest that COVID-19 aggravates the clinical course of alcoholic liver cirrhosis, leading to more severe phenotypes and higher mortality

Downloads

Download data is not yet available.

References

1. Marjot T, Webb GJ, Barritt AS et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348-364.

2. Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650-2666.

3. WHO. Clinical management of COVID-19: interim guidance. World Health Organization. 2020.

4. European Association for the Study of the Liver (EASL). Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181.

5. Yilmaz N, Yonal O, Kurt R. Impact of COVID-19 infection on liver disease patients. Turk J Gastroenterol. 2021;32(6):501-509.

6. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171.

7. Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol. 2016;13(3):131-149.

8. Kim D, Li AA, Perumpail RB et al. Changing trends in etiology-based annual mortality from chronic liver disease in the United States. Hepatology. 2019;69(3):1064-1074.

9. Abdullaeva M.A., Shodmonov U.Sh. Jigar kasalliklarida klinik ko‘rsatkichlarning tahlili. Tibbiyotda yangi kun. 2022; 2(38): 45–50.

10. Karimova D.I., Xolmatova S.A. COVID-19 infeksiyasining surunkali jigar kasalliklari bilan bog‘liqligi. O‘zbekiston Tibbiyot Jurnali. 2021; (4): 62–66.

11. Ismoilov A.B., Alimov N.T. Alkogolli jigar kasalliklarining klinik xususiyatlari. Gastroenterologiya va gepatologiya axborotnomasi. Toshkent, 2020; (3): 15–20.

12. Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377:756–768.

13. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038–1047.

14. Wong F, Piano S, Singh V, et al. Clinical features and evolution of COVID-19 in patients with cirrhosis: a multicenter study. J Hepatol. 2021;75(3):520–529.

15. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of decompensated cirrhosis. J Hepatol. 2018;69(2):406–460.